Home | Industry Information | Business News | Browse by Publication | K | Knight-Ridder Tribune Business News

Lilly wins Round 1 of Zyprexa battle.

Publication: Knight-Ridder Tribune Business News
Publication Date: 15-APR-05
Format: Online - approximately 1626 words
Delivery: Immediate Online Access

Article Excerpt
Byline: Jeff Swiatek

Apr. 15--A federal judge Friday upheld Eli Lilly and Co.'s Zyprexa patent, giving the drugmaker a critical and clear-cut court victory over generic drug challengers trying to cash in on Lilly's top-selling drug.

In his long-awaited decision, which came 14 months after a...

View more below

Read this article now - Try Goliath Business News - FREE!   
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News - Free for 7 Days!
Tell Me More   Terms and Conditions

Purchase this article for $4.95

Already a subscriber? Log in to view full article

...the patent infringement trial ended, U.S. District Court Judge Richard L. Young shot down all six legal claims made against the Zyprexa patent.

They included charges of double-patenting, getting patent on an invention that was obvious and misconduct before the patent office.

Any of the claims, if upheld, would have invalidated the U.S. patent on Lilly's all-time best-seller and sent the Indianapolis drugmaker reeling, as it faced the prospect of losing billions in revenue to generic rivals.

The ruling is "a huge relief," Lilly President Sidney Taurel said. "We expected to win, but until you have the decision, you still worry."

Taurel said the judge's decision "sends a clear message about the strength of these patents. This issue no longer clouds Lilly's future prospects."

Consumers gain, too, Taurel said, because Lilly will continue to have profits it was counting on to reinvest in the development of "innovative medicines."

But busting Lilly's patent, which runs to 2011, would have opened the door to generic companies to sell lower-priced Zyprexa to its many users. The pill is expensive, with the most common daily dose selling wholesale for $6.89 a pill. Zyprexa has been used by more than 16 million...

NOTE: All illustrations and photos have been removed from this article.



More articles from Knight-Ridder Tribune Business News
Southwest ends bonus to book online., April 19, 2005
Judge rules Maryland predatory-lending law cannot be applied to nation..., April 19, 2005
Definity Health to boost jobs at new offices., April 19, 2005
Shareholders of defunct Mirant protest firm's valuation at bankruptcy ..., April 19, 2005
Verizon plans to build switching center in Bakersfield, Calif., April 19, 2005

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.